All In Biotech

Drug Trial Radar · NCT05771155

Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®

A Randomized, Double-blind, Multicenter Phase 3 Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) to Compare the Efficacy, Safety and Immunogenicity of PB016 and Entyvio® for the Induction and Maintenance of Clinical Response and Remission

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

750

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Lead sponsor
Polpharma Biologics S.A.Industry
Sponsor type
Industry
First posted
Mar 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®

Conditions

  • Ulcerative Colitis

Interventions

  • Intravenous (IV) infusionsBiological

    Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate similarity of effect of induction treatment with IV formulations of PB016 and Entyvio® on clinical response rate at 6 weeksTime frame: Change from baseline to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Todua Clinic LLC

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.